{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:14:49Z","timestamp":1782936889895,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lanepe.2026.101710","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:58:59Z","timestamp":1778767139000},"page":"101710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and Safety Evidence Supporting Cancer Drug Approvals in Switzerland (2001\u20132020): A Meta-Analysis of Pivotal Randomised Controlled Trials"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-9795","authenticated-orcid":false,"given":"Parisa","family":"Rahimzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Rudofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Dalla Torre di Sanguinetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Miglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Bachir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bodmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6417-3066","authenticated-orcid":false,"given":"Ar\u016bnas","family":"Gir\u010dys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Juritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3409-8016","authenticated-orcid":false,"given":"Elisa","family":"Zaninotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-6152","authenticated-orcid":false,"given":"Matea","family":"Zosso-Pavic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Wolfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich-Peter","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-8080","authenticated-orcid":false,"given":"Andreas","family":"Wicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101710_bib1","series-title":"Cancer","year":"2025"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101710_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjconc-2025-000054","article-title":"Trends in pivotal clinical trial design and biomarker use: a retrospective analysis of oncology drug approval in Switzerland from 2001 to 2020","volume":"2","author":"Rahimzadeh","year":"2025","journal-title":"BMJ Connect Oncol"},{"key":"10.1016\/j.lanepe.2026.101710_bib3","series-title":"Benefit-risk assessment for new drug and biological products: guidance for industry","year":"2023"},{"issue":"33","key":"10.1016\/j.lanepe.2026.101710_bib4","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2008.16.5456","article-title":"Evolution of the randomized controlled trial in oncology over three decades","volume":"26","author":"Booth","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101710_bib5","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101710_bib6","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1093\/annonc\/mdq204","article-title":"Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?","volume":"21","author":"Soria","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101710_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jval.2014.06.006","article-title":"Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation","volume":"17","author":"J\u00f6nsson","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.lanepe.2026.101710_bib8","series-title":"Approaches to assessment of overall survival in oncology clinical trials: guidance for industry","year":"2025"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101710_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/annonc\/mdv562","article-title":"Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents","volume":"27","author":"Saad","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanepe.2026.101710_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102824","article-title":"Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward","volume":"76","author":"Mittal","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101710_bib11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00228-025-03822-w","article-title":"Era of surrogate endpoints and accelerated approvals: a comprehensive review on applicability, uncertainties, and challenges from regulatory, payer, and patient perspectives","volume":"81","author":"Sharma","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.lanepe.2026.101710_bib12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"issue":"35","key":"10.1016\/j.lanepe.2026.101710_bib13","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.22.00535","article-title":"Overall survival, progression-free survival, and tumor response benefit supporting initial US food and drug administration approval and indication extension of new cancer drugs, 2003-2021","volume":"40","author":"Michaeli","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101710_bib14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jnci\/djx232","article-title":"Magnitude of clinical benefit of cancer drugs approved by the US food and drug administration","volume":"110","author":"Tibau","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101710_bib15","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/ijc.34473","article-title":"The evidence base of US food and Drug Administration approvals of novel cancer therapies from 2000 to 2020","volume":"152","author":"Gloy","year":"2023","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101710_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.24406","article-title":"Clinical trial evidence supporting US food and drug administration approval of novel cancer therapies between 2000 and 2016","volume":"3","author":"Ladanie","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101710_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/bmjebm-2023-112544","article-title":"Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications","volume":"29","author":"Michaeli","year":"2024","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.lanepe.2026.101710_bib18","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101710_bib19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","article-title":"An overview of cancer drugs approved by the US Food and Drug administration based on the surrogate end point of response rate","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.lanepe.2026.101710_bib20","series-title":"ICH E2A: clinical safety data management: definitions and standards for expedited reporting","article-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use","year":"1994"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101710_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101710_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.35566\/jbds\/v3n2\/wang","article-title":"Conducting meta-analyses of proportions in R","volume":"3","author":"Wang","year":"2023","journal-title":"J Behav Data Sci"},{"key":"10.1016\/j.lanepe.2026.101710_bib23","series-title":"Meta-Analysis of Median Survival Times with Inverse-Variance Weighting","author":"McGrath","year":"2025"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101710_bib24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/jrsm.1686","article-title":"Metamedian: an R package for meta-analyzing studies reporting medians","volume":"15","author":"McGrath","year":"2024","journal-title":"Res Synth Methods"},{"issue":"17","key":"10.1016\/j.lanepe.2026.101710_bib25","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101710_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101710_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Software"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101710_bib28","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/cts.13567","article-title":"A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration","volume":"16","author":"Rohr","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101710_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268545","article-title":"Clinical benefit of cancer drugs approved in Switzerland 2010\u20132019","volume":"17","author":"Adam","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.lanepe.2026.101710_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101130","article-title":"Risks and benefits of anticancer drugs in advanced cancer patients: a systematic review and meta-analysis","volume":"40","author":"Moreau Bachelard","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101710_bib31","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/sim.3495","article-title":"A graphical approach to sequentially rejective multiple test procedures","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101710_bib32","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/cpt.3613","article-title":"Assessing correlation between surrogate endpoints and overall survival for oncology clinical trials","volume":"117","author":"Chu","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.lanepe.2026.101710_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115106","article-title":"Why effect sizes are systematically larger for progression-free survival than overall survival in cancer drug trials: prognostic scores as a way forward","volume":"213","author":"Locher","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101710_bib34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11136-026-04180-5","article-title":"Quality of life in oncology drug approvals: evidence from Swiss decisions in relation to global regulatory trends","volume":"35","author":"Horst","year":"2026","journal-title":"Qual Life Res"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101710_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-020-0368-0","article-title":"Informative censoring \u2014 a neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101710_bib36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226001225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226001225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:21:51Z","timestamp":1782894111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"alternative-id":["S2666776226001225"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101710","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety Evidence Supporting Cancer Drug Approvals in Switzerland (2001\u20132020): A Meta-Analysis of Pivotal Randomised Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101748","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101710"}}